» Articles » PMID: 11551841

Apoprotein C-III Deficiency Markedly Stimulates Triglyceride Secretion in Vivo: Comparison with Apoprotein E

Overview
Date 2001 Sep 12
PMID 11551841
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Apoprotein (apo) C-III plays an important role in the development of hypertriglyceridemia by inhibiting triglyceride (TG) removal. However, the effect of apo C-III on TG production remains unclear. We measured TG secretion rate (TGSR) in apo C-III gene-disrupted (apo C-III-null) mice to investigate the influence of this protein on TG turnover. TGSR measured by the Triton WR-1339 method was increased twofold in these mice compared with wild-type (WT) mice. Obesity was induced by the injection of gold-thioglucose (GTG), which made the WT mice hypertriglyceridemic due to a threefold increase of TGSR. However, GTG-induced obesity failed to increase TG in apo C-III-null mice, although TGSR was increased 10-fold, suggesting substantial stimulation of TG removal. Apo E-null mice were severely hypercholesterolemic but were not hypertriglyceridemic, and TGSR was rather decreased. GTG-induced obesity made these mice hypertriglyceridemic because of TG overproduction to an extent similar to that seen in WT mice. These results suggest that apo C-III deficiency potently enhances TG turnover, especially when TG production is stimulated, and that apo E deficiency is not always rate limiting for TG production.

Citing Articles

Cadmium exposure induces cardiac glucometabolic dysregulation and lipid accumulation independent of pyruvate dehydrogenase activity.

Oluranti O, Agboola E, Fubara N, Ajayi M, Michael O Ann Med. 2021; 53(1):1108-1117.

PMID: 34259114 PMC: 8280890. DOI: 10.1080/07853890.2021.1947519.


Attenuation of utero-toxicity, metabolic dysfunction and inflammation by soy protein concentrate in rats exposed to fluoridated water: consequence of hyperlipidemia in parallel with hypohomocysteinemia.

Jana L, Maity P, Perveen H, Dash M, Jana S, Dey A Environ Sci Pollut Res Int. 2018; 25(36):36462-36473.

PMID: 30374712 DOI: 10.1007/s11356-018-3542-5.


Pathophysiology of Diabetic Dyslipidemia.

Hirano T J Atheroscler Thromb. 2018; 25(9):771-782.

PMID: 29998913 PMC: 6143775. DOI: 10.5551/jat.RV17023.


The Foxo1-Inducible Transcriptional Repressor Zfp125 Causes Hepatic Steatosis and Hypercholesterolemia.

Fernandes G, Bocco B, Fonseca T, McAninch E, Jo S, Lartey L Cell Rep. 2018; 22(2):523-534.

PMID: 29320745 PMC: 6474669. DOI: 10.1016/j.celrep.2017.12.053.


Experimental Biology for the Identification of Causal Pathways in Atherosclerosis.

Guo Y, Garcia-Barrio M, Wang L, Chen Y Cardiovasc Drugs Ther. 2016; 30(1):1-11.

PMID: 26847647 PMC: 7088260. DOI: 10.1007/s10557-016-6644-7.